Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results

• Published in: Clinical rheumatology Vol. 41; no. 5; pp. 1439 - 1446
• Main Authors: Ayan, Gizem, Farisogulları, Bayram, Bilgin, Emre, Bolek, Ertugrul Cagri, KübraYardımcı, Gozde, Duran, Emine, Ozsoy, Zehra, Uzun, Gullu Sandal, Kilic, Levent, Akdoğan, Ali, Karadag, Omer, Bilgen, Şule Apraş, Kiraz, Sedat, Ertenli, Ali İhsan, Kalyoncu, Umut
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2022; Springer Nature B.V
• Subjects: Adult; Antirheumatic Agents - therapeutic use; Anxiety; Arthritis; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - epidemiology; Biological Products - therapeutic use; Correlation analysis; Female; Humans; HuR protein; Male; Medicine; Medicine & Public Health; Original Article; Patients; Psoriatic arthritis; Registries; Rheumatology; Severity of Illness Index; Registry; bDMARD; Comorbidity; Outcome
• ISSN: 0770-3198; 1434-9949
• DOI: 10.1007/s10067-021-06012-y

Objectives Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease related to several comorbidities . Anxiety is an important comorbidity in PsA and the data is scarce. We aimed to understand the rates before biologic agents and change in anxiety with the treatment. Methods PsA patients from the Hacettepe University biologic database (HUR-BIO) were assessed for the high anxiety level (score ≥ 4) using the patient self-reported measure of anxiety on a 0–10 numerical scale, included in the Psoriatic Arthritis Impact of Disease questionnaire (PSAID-12). The rate and scores of anxiety were determined before starting biologic agents, at the first visit within 6 months. Changes in anxiety scores were assessed according to favorable treatment responses, and the correlation was evaluated by Spearman correlation analysis. Results From 520 patients registered, 147 [mean (SD) age 43.3 (12.4) years, 70.7% female] had anxiety score both at baseline and first visit within 6 months. Both the frequency of high anxiety level and mean (SD) scores decreased at the first visit [63.9% vs. 41.4%, 4.8 (3.4) vs. 3.2 (3.1) respectively, p  < 0.001 for both] after a mean (SD) follow-up of 105.7 (22.2) days. There was also a positive correlation between the change in anxiety scores and all parameters tested for treatment response: pain, PGA, BASDAI, HAQ-DI, DAS-28, and also PsAID-12. Conclusion Anxiety is a more frequent problem at biologic initiation than rates observed in the general PsA population. The rates show a decreasing trend and correlates with treatment response but is still high within 6 months under treatment. Key Points • As high as 65% of patients had a high anxiety levels before the initiation of bDMARDs. • The disease activity control is essential in reducing anxiety; however, rates are still high within 6 months. • Decreased anxiety scores and rates of the high anxiety level are linked to better outcomes.